Retlirafusp alfa with chemo or fuzuloparib for triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new drug called retlirafusp alfa, which may boost the immune system, when combined with chemotherapy or another drug (fuzuloparib) for people with triple-negative breast cancer that has spread or come back, or is at high risk of coming back. The goal is to see if the combination helps shrink tumors or prevents cancer from returning.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have been diagnosed with triple-negative breast cancer (meaning your cancer does not have receptors for estrogen, progesterone, or HER2).
- Your cancer has spread to other parts of the body (metastatic), cannot be fully removed by surgery, or is in an early stage but has a high risk of returning.
- You must have at least one tumor that can be measured on a scan.
- You must be able to provide a tissue sample from your cancer for testing, and your BRCA gene status must be known.
- You have not had certain previous treatments, such as immunotherapy (like PD-1 or PD-L1 inhibitors), PARP inhibitors (like olaparib), or TGF-beta inhibitors.
- Your overall health, heart, kidney, liver, and blood counts must be within acceptable ranges as determined by routine tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (camrelizumab and pirfenidone) with chemotherapy to see if it can help people with advanced triple-negative breast cancer. It may offer a new treatment option for those whose cancer has progressed after initial treatment.
This trial tests an experimental drug called QLC5513, either by itself or combined with another drug (QL1706), for people with triple-negative breast cancer that has continued to grow despite prior treatment. The goal is to see if this new approach can shrink tumors or slow the cancer's progression, and it might be an option if standard treatments have stopped working.
This trial tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) with a PARP inhibitor (olaparib) and a chemotherapy drug (paclitaxel) before surgery for early high-risk triple negative breast cancer that is HRD positive. It aims to shrink or eliminate the tumor to improve long-term outcomes.
This study tests a combination of two drugs — an immunotherapy (QL1706) and a PARP inhibitor (olaparib) — to see if it can help people with triple-negative breast cancer that has come back or spread, especially when their tumors have a specific DNA repair problem (HRD). It is for people who have already tried at least one prior treatment.
This study tests whether adding a drug called everolimus to a targeted therapy called trastuzumab rezetecan is more effective than the targeted therapy alone for people with a specific type of triple-negative breast cancer (called LAR subtype) that has spread or come back. The combination aims to improve treatment response and potentially help you live longer.
This trial tests whether adding a PARP inhibitor or capecitabine (chemo) to a PD-1 inhibitor (immunotherapy) after surgery helps prevent triple-negative breast cancer from coming back. It's for people with high-risk disease who have completed initial treatment.
Hear when a new Triple-Negative Breast Cancer (TNBC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.